Observational, Bi-directional (Prospective and Retrospective) Study for Patients With Newly Diagnosed Ovarian Cancer Stages IA to IVB, or Persistent or Recurrent Disease From January 2021; Irrespective of Histology
Recruiting
Observational Study
Ovarian Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Female
- Study type
- Observational
- Participants needed
- 250 (estimated)
- Sponsor
- AstraZeneca · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The findings from this study have the potential to serve as a foundation for evaluating the current practices related to surgical procedures, systemic therapies, hyperthermic intraperitoneal chemotherapy, and referrals to geneticists for OC patients. By identifying the strengths and weaknesses of the existing care, this project intends to generate valuable insights that can lead to the implementat…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients ≥18 years old;
* Newly diagnosed ovarian cancer stages IA to IVB, or persistent or recurrent disease from January 2021;
* Irrespective of histology
Exclusion Criteria:
* Borderline tumors;
* Pregnancy;
* Synchronous tumor or second primary in the last 5 years (excep…
Contacts
AstraZeneca Clinical Study Information Center
1-877-240-9479
information.center@astrazeneca.com
CONTACT